PVAX-hSlo is under clinical development by Urovant Sciences and currently in Phase II for Urinary Incontinence. According to GlobalData, Phase II drugs for Urinary Incontinence have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PVAX-hSlo’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PVAX-hSlo overview
pVAX-hSlo (hmaxi-K) gene transfer therapy is under development for the treatment of urinary incontinence. pVAX-hSlo (hmaxi-K) gene is administered by intradetrusor injection, intravesical instillation, intracavernous and intramuscular injection. hmaxi-K gene is a double stranded naked plasmid DNA (nucleic acid) molecule carrying the human cDNA encoding the alpha, or pore forming a subunit of the human smooth muscle maxi-K channel hSlo. hSlo is under control of the CMV promoter positioned upstream of the transgene and the construct also contains the Bovine Growth Hormone poly A site, kanamycin resistance gene and pUC origin of replication.
It was also under development for erectile dysfunction and overactive bladder syndrome.
Urovant Sciences overview
Urovant Sciences (Urovant) is a clinical-stage biopharmaceutical company which develops and commercializes novel therapies for urologic conditions. The company’s pipeline products include vibegron, is an oral small molecule beta-3 agonist -adrenergic agonist for the treatment of overactive bladder. Urovant also provides hMaxi-K, is a new genetic therapy for patients with overactive bladder who have failed oral pharmacologic therapy. It develops products for the treatment of benign prostatic hyperplasia (BPH) and irritable bowel syndrome (IBS). Urovant is headquartered in Irvine, California, the US.
For a complete picture of PVAX-hSlo’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - pVAX-hSlo in Urinary Incontinence
Premium Insights
The gold standard of business intelligence.
